Get the Stockscreener App
67.09
3.31%
2.15
Bridgebio Pharma Inc stock is traded at $67.09, with a volume of 1.02M.
It is up +3.31% in the last 24 hours and down -1.90% over the past month.
BridgeBio Pharma is a biotechnology company focused on discovering, developing, testing, and delivering transformative treatments for patients with genetic diseases. The company has four programs in its late-stage pipeline focusing on Mendelian disorders, oncology, and gene therapy. One of its key programs, Attruby (acoramidis), is an orally administered small molecule designed to stabilize tetrameric transthyretin for the treatment of transthyretin amyloid cardiomyopathy.
See More
Previous Close:
$64.94
Open:
$65.67
24h Volume:
1.02M
Relative Volume:
0.38
Market Cap:
$13.12B
Revenue:
$579.96M
Net Income/Loss:
$-729.89M
P/E Ratio:
-17.91
EPS:
-3.7459
Net Cash Flow:
$-452.02M
1W Performance:
+3.15%
1M Performance:
-1.90%
6M Performance:
-13.66%
1Y Performance:
+18.47%
1-Day Range:
$65.44
$67.48
1-Week Range:
$62.86
$66.42
52-Week Range:
$52.75
$93.42
Bridgebio Pharma Inc Stock (BBIO) Company Profile
Name
Bridgebio Pharma Inc
Sector
Industry
Phone
(650) 391-9740
Address
3160 PORTER DR., PALO ALTO, CA
Compare BBIO vs VRTX, MRNA, REGN, ARGX, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
BBIO
Bridgebio Pharma Inc
|
67.09 | 13.12B | 579.96M | -729.89M | -452.02M | -3.7459 |
VRTX
Vertex Pharmaceuticals Inc
|
509.72 | 129.19B | 12.34B | 4.34B | 3.71B | 16.87 |
MRNA
Moderna Inc
|
237.78 | 94.93B | 2.23B | -3.19B | -1.60B | -8.1462 |
REGN
Regeneron Pharmaceuticals Inc
|
801.11 | 82.48B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
848.35 | 53.35B | 4.16B | 1.29B | 734.26M | 19.58 |
ONC
Beone Medicines Ltd Adr
|
371.37 | 42.01B | 5.76B | 514.49M | 1.10B | 4.4813 |
Bridgebio Pharma Inc Stock (BBIO) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jun-03-26 | Initiated | Canaccord Genuity | Buy |
| May-26-26 | Downgrade | Raymond James | Outperform → Mkt Perform |
| May-19-26 | Initiated | Citigroup | Neutral |
| Apr-09-26 | Initiated | RBC Capital Mkts | Outperform |
| Mar-10-26 | Initiated | William Blair | Outperform |
| Jan-28-26 | Initiated | Barclays | Overweight |
| Jan-06-26 | Initiated | Morgan Stanley | Overweight |
| Dec-11-25 | Initiated | Bernstein | Outperform |
| Jul-30-25 | Resumed | Raymond James | Outperform |
| Jul-21-25 | Initiated | Truist | Buy |
| Jul-14-25 | Initiated | Jefferies | Buy |
| Jul-09-25 | Upgrade | Oppenheimer | Perform → Outperform |
| Jun-17-25 | Initiated | Wolfe Research | Outperform |
| Mar-31-25 | Initiated | Redburn Atlantic | Buy |
| Oct-16-24 | Initiated | Scotiabank | Sector Outperform |
| Oct-03-24 | Initiated | Oppenheimer | Perform |
| Sep-04-24 | Initiated | Piper Sandler | Overweight |
| Mar-21-24 | Resumed | Raymond James | Outperform |
| Jan-31-24 | Initiated | BMO Capital Markets | Market Perform |
| Dec-08-23 | Initiated | Wells Fargo | Overweight |
| Nov-07-23 | Initiated | Citigroup | Buy |
| Oct-24-23 | Initiated | Cantor Fitzgerald | Overweight |
| Jul-18-23 | Downgrade | Jefferies | Buy → Hold |
| Apr-19-23 | Initiated | Evercore ISI | Outperform |
| Feb-06-23 | Initiated | Cowen | Outperform |
| Dec-27-21 | Reiterated | Mizuho | Buy |
| Dec-27-21 | Reiterated | SVB Leerink | Outperform |
| Sep-10-21 | Upgrade | BofA Securities | Neutral → Buy |
| May-21-21 | Initiated | UBS | Buy |
| Mar-22-21 | Reiterated | Goldman | Buy |
| Feb-22-21 | Resumed | JP Morgan | Overweight |
| Feb-09-21 | Resumed | Goldman | Buy |
| Jan-11-21 | Reiterated | H.C. Wainwright | Buy |
| Dec-10-20 | Reiterated | H.C. Wainwright | Buy |
| Jun-25-20 | Initiated | BofA/Merrill | Neutral |
| May-19-20 | Initiated | BTIG Research | Buy |
| Apr-13-20 | Initiated | H.C. Wainwright | Buy |
| Feb-19-20 | Initiated | Mizuho | Buy |
| Jul-26-19 | Initiated | Raymond James | Outperform |
| Jul-22-19 | Initiated | BMO Capital Markets | Outperform |
| Jul-22-19 | Initiated | Goldman | Buy |
| Jul-22-19 | Initiated | JP Morgan | Overweight |
| Jul-22-19 | Initiated | Jefferies | Buy |
| Jul-22-19 | Initiated | Piper Jaffray | Overweight |
| Jul-22-19 | Initiated | SVB Leerink | Outperform |
View All
Bridgebio Pharma Inc Stock (BBIO) Latest News
Acoramidis Associated with Significantly Improved Clinical Outcomes Versus Tafamidis in ATTR-CM in an Independent, Real-World Study of U.S. Electronic Health Records - GlobeNewswire Inc.
Encaleret Increased Bone Turnover and Improved Participant-Reported Symptoms in the Phase 3 CALIBRATE Trial in ADH1 - GlobeNewswire Inc.
FDA Grants Priority Review to BridgeBio's Dwarfism Drug Filing - Zacks Investment Research
BridgeBio Pharma CEO Neil Kumar sells $690,847 in shares - Investing.com
BridgeBio Pharma CEO Neil Kumar sells $690,847 in shares By Investing.com - Investing.com Nigeria
BridgeBio (NASDAQ: BBIO) CEO’s trust sells 10,000 shares under preset plan - Stock Titan
BridgeBio Pharma stock gains attention as fresh inducement grants highlight growth plans - AD HOC NEWS
BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) - Yahoo Finance
133,900 Preferred Stock of BridgeBio Pharma, Inc. are subject to a Lock-Up Agreement Ending on 13-SEP-2026. - marketscreener.com
Bio-Rad Laboratories, Inc. at Wells Fargo Healthcare Conference Transcript - GuruFocus
Analysts Offer Insights on Healthcare Companies: BridgeBio Pharma (BBIO), EyePoint Pharmaceuticals (EYPT) and Abbott Laboratories (ABT) - The Globe and Mail
H.C. Wainwright Maintains BridgeBio Pharma(BBIO.US) With Buy Rating, Maintains Target Price $120 - Moomoo
BIO-RAD LABORATORIES (NYSE: BIO) Grants 719 Derivative Securities to Director Allison Schwartz - Kalkine Media
BridgeBio at Cantor global healthcare conference: launch pipeline in focus By Investing.com - Investing.com Nigeria
BIO-RAD LABORATORIES Executive Evran Sedat Reports Exercising 3,880 Shares (NYSE: BIO) - Kalkine Media
BridgeBio at Cantor global healthcare conference: launch pipeline in focus By Investing.com - Investing.com Canada
Bio-Rad: Favorable Read-Across From Investor Event (NYSE:BIO) - Seeking Alpha
BBIO Reiterated by HC Wainwright & Co. -- Rating Maintained at B - GuruFocus
BridgeBio Pharma: Attruby Peak Sales Set To Rise - Seeking Alpha
H.C. Wainwright reiterates BridgeBio Pharma stock rating at buy By Investing.com - Investing.com India
H.C. Wainwright reiterates BridgeBio Pharma stock rating at buy By Investing.com - Investing.com Canada
Bio-Rad (NYSE: BIO) director sees 320 RSUs convert, 116 shares withheld - Stock Titan
[Form 4] BIO-RAD LABORATORIES, INC. Insider Trading Activity - Stock Titan
Bio-Rad (NYSE: BIO) EVP logs 4,313 RSU grant and 2,179 vested shares - Stock Titan
[Form 4] BIO-RAD LABORATORIES, INC. Insider Trading Activity - Stock Titan
1,453 stock units vest for Bio-Rad (NYSE: BIO) insider as 551 shares withheld - Stock Titan
Bio-Rad (NYSE: BIO) grants EVP 4,601 RSUs, with shares withheld at $386.11 - Stock Titan
[Form 4] BIO-RAD LABORATORIES, INC. Insider Trading Activity - Stock Titan
Bio-Rad at Wells Fargo conference: margin push takes center stage - Investing.com Canada
Bio-Rad at Wells Fargo conference: margin push takes center stage - Investing.com India
Bio-Rad at Wells Fargo conference: margin push takes center stage - Investing.com UK
BridgeBio at Wells Fargo conference: growth plan centers on 2027 launches - Investing.com India
Bio-Rad Terminates Forbes Tate Lobbying Pact - Legis1
BBIO: Multiple late-stage therapies targeting rare genetic diseases set for US launches by 2027 - TradingView
Why (BBIO) Price Action Is Critical for Tactical Trading - Stock Traders Daily
BridgeBio Pharma (BBIO) Down 10.7% Since Last Earnings Report: Can It Rebound? - Yahoo Finance
BridgeBio Dwarfism Data Shows Broad Health Benefits Beyond Height Gain - Benzinga
BridgeBio reports Phase 3 infigratinib achondroplasia data - grafa.com
BridgeBio Oncology Therapeutics, Inc. SEC Filing (Sep 9, 2026) - stocktitan.net
13 Red Days In A Row: BridgeBio Pharma Stock Is Down 11% - Trefis
BridgeBio’s infigratinib shows improvements in achondroplasia study By Investing.com - Investing.com Nigeria
BBIO Looks 51.2% Undervalued on GF Value™ Despite Profitability Challenges - GuruFocus
BridgeBio’s infigratinib shows improvements in achondroplasia study By Investing.com - Investing.com Canada
BridgeBio’s infigratinib shows improvements in achondroplasia study - investing.com
Achondroplasia Market Analysis Report 2026: Emerging Pipeline Intensifies Competition, Featuring Ascendis Pharma, BioMarin Pharmaceutical, QED Therapeutics (BridgeBio), Novartis, Kyowa Kirin, RIBOMIC - Yahoo Finance
BridgeBio Pharma Reports Favorable Exploratory PROPEL 3 Data for Oral Infigratinib in Achondroplasia, Including Sleep Apnea and Ear Infection Trends - Quiver Quantitative
BridgeBio’s infigratinib shows improvements in achondroplasia study By Investing.com - Investing.com UK
A sleep-apnea measure rose 10.4% with an experimental drug, versus 49.2% with placebo - Stock Titan
Bio-Rad expands range of Foresight prepacked chromatography columns for biomanufacturing - selectscience.net
Bridgebio Pharma Inc Stock (BBIO) Financials Data
Revenue
Net Income
Cash Flow
EPS
Bridgebio Pharma Inc Stock (BBIO) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| KUMAR HALDEA FAMILY IRREVOCABL | Director |
Aug 19 '26 |
Proposed Sale |
82.98 |
30,000 |
2,489,400 |
0 |
| Kumar Neil | Chief Executive Officer |
Aug 19 '26 |
Sale |
84.03 |
10,000 |
840,257 |
505,686 |
| Kumar Neil | Chief Executive Officer |
Aug 18 '26 |
Sale |
82.53 |
34,980 |
2,886,994 |
243,327 |
| NEIL KUMAR | Director |
Aug 18 '26 |
Proposed Sale |
79.89 |
34,980 |
2,794,552 |
0 |
| RANDAL SCOTT | Director |
Aug 17 '26 |
Proposed Sale |
79.86 |
21,501 |
1,717,070 |
0 |
| Apuli Maricel | Chief Accounting Officer |
Jul 30 '26 |
Sale |
80.06 |
2,000 |
160,120 |
127,401 |
| Ellis Andrea | Director |
Jul 09 '26 |
Option Exercise |
16.75 |
17,167 |
287,547 |
39,746 |
| ANDREA ELLIS | Director |
Jul 09 '26 |
Proposed Sale |
84.00 |
17,167 |
1,442,028 |
0 |
| JENNIFER COOK | Director |
Jul 09 '26 |
Proposed Sale |
88.54 |
148,589 |
13,156,008 |
0 |
| Cook Jennifer E. | Director |
Jul 09 '26 |
Sale |
88.54 |
148,589 |
13,156,008 |
8,383 |
3.96%
1.69%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):